A Double-blind, Placebo-controlled, Randomised, Parallel Group, Single Centre, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.

Trial Profile

A Double-blind, Placebo-controlled, Randomised, Parallel Group, Single Centre, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs DSP 3025 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 27 Apr 2012 Primary endpoints identified as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top